DK2115477T3 - Anvendelse af igfbp-7 i bedømmelsen af hjertesvigt - Google Patents

Anvendelse af igfbp-7 i bedømmelsen af hjertesvigt Download PDF

Info

Publication number
DK2115477T3
DK2115477T3 DK08707286.4T DK08707286T DK2115477T3 DK 2115477 T3 DK2115477 T3 DK 2115477T3 DK 08707286 T DK08707286 T DK 08707286T DK 2115477 T3 DK2115477 T3 DK 2115477T3
Authority
DK
Denmark
Prior art keywords
marker
igfbp
heart failure
protein
sample
Prior art date
Application number
DK08707286.4T
Other languages
English (en)
Inventor
Ursula-Henrike Wienhues-Thelen
Dirk Block
Andrew Emili
Vincent Fong
Anthony Gramolini
Georg Hess
Ruth Isserlin
Thomas Kislinger
Peter Liu
David Maclennan
Hendrik Huedig
Der Eltz Herbert Von
Original Assignee
Hoffmann La Roche
Univ Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Univ Toronto filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2115477T3 publication Critical patent/DK2115477T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (8)

1. In vitro-fremgangsmåde til at bedømme hjertesvigt hos et individ omfattende trinnene at a) måle koncentrationen af markørproteinet insulin-lignende vækstfaktorbindingsprotein 7 (IGFBP-7) i en prøve opnået fra individet, og b) bedømme hjertesvigt ved at sammenligne koncentrationen bestemt i trin (a) med koncentrationen af dette markørprotein som konstateret i en kontrolprøve, hvori en øget værdi af IGFBP-7 er indikation for hjertesvigt, yderligere kendetegnet ved at prøven er valgt fra gruppen bestående af serum, plasma, og fuldblod.
2. In vitro-fremgangsmåde ifølge krav 1, yderligere omfattende måling af ét eller flere markørprotein(er) for hjertesvigt valgt fra gruppen bestående af en natriuretisk peptidmarkør, en hjertetroponinmarkør, og en inflammationsmarkør.
3. In vitro-fremgangsmåde ifølge krav 2, yderligere kendetegnet ved at det ene eller flere andre markørprotein(er) er NT-proBNP.
4. In vitro-fremgangsmåde ifølge krav 2, yderligere kendetegnet ved at det ene eller flere andre markørprotein(er) er troponin T.
5. Anvendelse af protein IGFBP-7 som markørmolekyle i in vitro-bedømmelsen for hjertesvigt, hvor detektion af et øget niveau er IGFBP-7 i en prøve opnået fra et individ sammenlignet med en kontrolprøve er indikation for hjertesvigt, yderligere kendetegnet ved at prøven er valgt fra gruppen bestående af serum, plasma, og fuldblod.
6. Anvendelse af en markørkombination omfattende protein IGFBP-7 og ét eller flere andre markørprotein(er) for hjertesvigt i in vitro-bedømmelsen for hjertesvigt, hvor detektion af et øget niveau er IGFBP-7 i en prøve opnået fra et individ sammenlignet med en kontrolprøve er indikation for hjertesvigt, yderligere kendetegnet ved at prøven er valgt fra gruppen bestående af serum, plasma, og fuldblod.
7. Anvendelse af markørkombinationen ifølge krav 6, hvor det ene eller flere andre markørprotein(er) er valgt fra gruppen bestående afen natriuretisk peptidmarkør, en hjertetroponinmarkør, og en inflammationsmarkør.
8. Anvendelse af en markørkombination ifølge krav 7 omfattende mindst IGFBP-7, og NT-proBNP.
DK08707286.4T 2007-01-25 2008-01-25 Anvendelse af igfbp-7 i bedømmelsen af hjertesvigt DK2115477T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07001582 2007-01-25
PCT/EP2008/000576 WO2008089994A1 (en) 2007-01-25 2008-01-25 Use of igfbp-7 in the assessment of heart failure

Publications (1)

Publication Number Publication Date
DK2115477T3 true DK2115477T3 (da) 2015-08-10

Family

ID=37810309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08707286.4T DK2115477T3 (da) 2007-01-25 2008-01-25 Anvendelse af igfbp-7 i bedømmelsen af hjertesvigt

Country Status (10)

Country Link
US (4) US20100285491A1 (da)
EP (2) EP2498095A3 (da)
JP (1) JP2010517023A (da)
CN (2) CN106908603B (da)
CA (1) CA2671298C (da)
DK (1) DK2115477T3 (da)
ES (1) ES2548009T3 (da)
HU (1) HUE025408T2 (da)
PL (1) PL2115477T3 (da)
WO (1) WO2008089994A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2115477T3 (da) * 2007-01-25 2015-08-10 Hoffmann La Roche Anvendelse af igfbp-7 i bedømmelsen af hjertesvigt
EP2399131B1 (en) * 2009-02-20 2014-08-27 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Method for the diagnosis of age-associated vascular disorders
ES2512018T3 (es) * 2009-07-27 2014-10-23 F. Hoffmann-La Roche Ag Utilización de mimecán en la evaluación de la insuficiencia cardiaca
CA2772336A1 (en) * 2009-08-28 2011-03-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
SI2666872T1 (sl) 2010-02-05 2016-08-31 Astute Medical, Inc. Postopki in sestavki za diagnozo in prognozo ledvične poškodbe in odpovedi ledvic
ES2627337T3 (es) * 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
FI20115367A0 (fi) * 2011-04-15 2011-04-15 Hytest Oy Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
BR122021026652B1 (pt) 2011-10-17 2022-08-23 F. Hoffmann-La Roche Ag Método in vitro para diagnosticar fibrilação atrial intermitente, uso de uma troponina cardíaca e dispositivo para diagnosticar fibrilação atrial intermitente
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2713098T3 (es) * 2012-08-09 2019-05-17 Inst Nat Sante Rech Med Diagnóstico de insuficiencia cardíaca
EP2895866B1 (en) * 2012-09-12 2018-05-30 Roche Diagnostics GmbH Identification of patients with abnormal fractional shortening
EP2730923A1 (en) * 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP and cTnT based therapy guidance in heart failure
EP2929354B1 (en) * 2012-12-04 2018-04-18 Roche Diagnostics GmbH Biomarkers in the selection of therapy of heart failure
ES2681955T3 (es) 2013-01-17 2018-09-17 Astute Medical, Inc. Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
RS58694B1 (sr) 2013-06-06 2019-06-28 Inst Nat Sante Rech Med Biomarker ponovne hospitalizacije nakon srčane insuficijencije
EP2843414B1 (en) * 2013-08-26 2018-09-19 Roche Diagniostics GmbH Marker for statin treatment stratification in heart failure
CA3185700A1 (en) * 2013-11-06 2015-05-14 Astute Medical, Inc. Assays for igfbp7 having improved performance in biological samples
JP2016540759A (ja) 2013-12-03 2016-12-28 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
ES2712201T3 (es) * 2014-01-28 2019-05-09 Hoffmann La Roche Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B
ES2939018T3 (es) * 2014-03-26 2023-04-18 Hoffmann La Roche IGFBP7 para diagnosticar una disfunción diastólica
CN103926401A (zh) * 2014-03-31 2014-07-16 瑞莱生物科技（江苏）有限公司 一种快速定量检测igfbp-7和timp-2的免疫荧光试纸条及其制备方法
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3213085B2 (en) * 2014-10-29 2022-09-28 Roche Diagnostics GmbH Biomarkers for risk prediction of progression of chronic heart failure and mortality
CN104408717A (zh) * 2014-11-24 2015-03-11 北京航空航天大学 一种基于着色分离的病理图像颜色质量综合评价方法
EP3281011B1 (en) 2015-04-09 2024-06-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP7080176B2 (ja) 2016-02-29 2022-06-03 エフ．ホフマン－ラ ロシュ アーゲー 子癇前症におけるマーカーとしてのｉｇｆｂｐ－７
WO2017214203A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
EP3472622B1 (en) * 2016-06-17 2020-08-05 Roche Diagnostics GmbH Circulating angiopoietin-2 (ang-2) for the prediction of recurrence of atrial fibrillation
US10865412B2 (en) * 2016-11-04 2020-12-15 Ottawa Heart Institute Research Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases
CN111480081A (zh) 2017-12-13 2020-07-31 豪夫迈·罗氏有限公司 用于预测脑卒中的循环血管生成素-2(Ang-2)和胰岛素样生长因子结合蛋白7(IGFBP7)
CN112673259A (zh) 2018-07-20 2021-04-16 豪夫迈·罗氏有限公司 基于igfbp-7的先兆子痫预测
KR20210044216A (ko) 2018-08-10 2021-04-22 에프. 호프만-라 로슈 아게 심방세동-관련 뇌졸중 평가를 위한 ces-2 (카르복실에스테라제-2)
JP2021535370A (ja) 2018-08-16 2021-12-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 心房細動および抗凝固療法の評価における循環ｔｆｐｉ−２（組織因子経路阻害剤２）
EP3841381A1 (en) 2018-08-22 2021-06-30 Roche Diagnostics GmbH Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
WO2020039085A1 (en) 2018-08-24 2020-02-27 Roche Diagnostics Gmbh Circulating fgfbp-1 (fibroblast growth factor-binding protein 1) in the assessment of atrial fibrillation and for the prediction of stroke
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
EP3951387A4 (en) * 2019-03-29 2022-11-23 Eiken Kagaku Kabushiki Kaisha MARKERS OF ARTERIOSCLEROSIS AND ARTERIOSCLEROSIS RELATED DISEASES
WO2020234451A1 (en) 2019-05-23 2020-11-26 Roche Diagnostics Gmbh IGFBP7 RATIO FOR HFpEF
JP2023537749A (ja) 2020-08-14 2023-09-05 エフ． ホフマン－ラ ロシュ アーゲー 無症候性脳梗塞及び認知低下の評価のためのｉｇｆｂｐ７
WO2023175152A1 (en) 2022-03-18 2023-09-21 Roche Diagnostics Gmbh Troponin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174A (en) 1849-03-13 Improvement in balances for weighing
US686A (en) 1838-04-13 Machine foe faking- and goring
US6333397B1 (en) 1989-04-25 2001-12-25 Roche Diagnostics Gmbh Monoclonal antibodies to troponin T and their production
DE3922873A1 (de) 1989-04-25 1990-10-31 Boehringer Mannheim Gmbh Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen
JPH07132095A (ja) 1993-06-11 1995-05-23 Nawata Arata Ｄｎａおよびそのコードする蛋白質
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
DE69633780T3 (de) * 1995-04-18 2011-05-05 Biosite Incorporated, San Diego Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays
AU2055400A (en) 1998-12-18 2000-07-03 Human Genome Sciences, Inc. Prostacyclin-stimulating factor-2
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
AU2055300A (en) * 1998-12-18 2000-07-03 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
ATE403158T1 (de) * 1999-01-29 2008-08-15 Roche Diagnostics Gmbh Verfahren zum nachweis von n-terminalem probnp
AU2001274536A1 (en) 2000-06-15 2002-01-02 Kyowa Hakko Kogyo Co. Ltd. Insulin-like growth factor-binding protein
US20030119009A1 (en) * 2001-02-23 2003-06-26 Stuart Susan G. Genes regulated by MYCN activation
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
GB0130557D0 (en) 2001-12-20 2002-02-06 Serono Internat S A Proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
PL2256132T3 (pl) 2003-05-12 2016-08-31 Hoffmann La Roche Sposób wykrywania proBNP z zastosowaniem przeciwciała monoklonalnego
GB0329288D0 (en) * 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
US20060003338A1 (en) 2004-06-30 2006-01-05 Deng David X System and methods for the management and treatment of vascular graft disease
US7659091B2 (en) * 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
ITVI20050059A1 (it) 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
US20090054741A1 (en) * 2005-03-29 2009-02-26 Inverness Medical Switzerland Gmbh Device and method of monitoring a patient
DE102005014752A1 (de) * 2005-03-31 2006-11-23 Johannes-Gutenberg-Universität Mainz Entzündungsmarker und Kombinationen davon als biochemische Marker bei kardiovaskulären Erkrankungen
EP1722232A1 (en) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
EP2500723B1 (en) * 2006-11-14 2015-07-08 Alere San Diego, Inc. Methods for monitoring and risk prediction in cardiorenal syndrome
DK2115477T3 (da) * 2007-01-25 2015-08-10 Hoffmann La Roche Anvendelse af igfbp-7 i bedømmelsen af hjertesvigt
EP1967853B1 (en) * 2007-03-06 2010-01-27 Roche Diagnostics GmbH Use of Nogo-C in the assessment of heart failure
CA2680339C (en) * 2007-03-08 2017-02-28 F. Hoffmann-La Roche Ag Use of slim-1 in the assessment of heart failure
ES2512018T3 (es) * 2009-07-27 2014-10-23 F. Hoffmann-La Roche Ag Utilización de mimecán en la evaluación de la insuficiencia cardiaca

Also Published As

Publication number Publication date
US10996229B2 (en) 2021-05-04
CA2671298A1 (en) 2008-07-31
HUE025408T2 (hu) 2016-02-29
EP2498095A2 (en) 2012-09-12
CA2671298C (en) 2020-07-28
PL2115477T3 (pl) 2015-12-31
US20200064359A1 (en) 2020-02-27
CN101636656A (zh) 2010-01-27
EP2115477B1 (en) 2015-06-24
EP2498095A3 (en) 2012-11-28
CN106908603B (zh) 2019-04-02
US20170016918A1 (en) 2017-01-19
US10488422B2 (en) 2019-11-26
JP2010517023A (ja) 2010-05-20
US20100285491A1 (en) 2010-11-11
US20150293122A1 (en) 2015-10-15
WO2008089994A1 (en) 2008-07-31
EP2115477A1 (en) 2009-11-11
CN106908603A (zh) 2017-06-30
WO2008089994A8 (en) 2009-05-22
ES2548009T3 (es) 2015-10-13

Similar Documents

Publication Publication Date Title
US10996229B2 (en) Use of IGFBP-7 in the assessment of heart failure
CA2769243C (en) Use of mimecan in the assessment of heart failure
US9267954B2 (en) Use of SLIM-1 in the assessment of heart failure
EP2425245B1 (en) Use of endostatin as a marker of heart failure
US20160146836A1 (en) Use of alpha-crystallin b (cryab) in the assessment of heart failure
US20140193845A1 (en) Use of sfrp-3 in the assessment of heart failure
EP1967853B1 (en) Use of Nogo-C in the assessment of heart failure
US20110165591A1 (en) Use of biglycan in the assessment of heart failure